Dhanuka Agritech Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - Management discusses ongoing investments, such as CAPEX of Rs. 60-70 crores for the MPP-2 plant but does not specify funding sources. - Current cash on books is more than Rs. 250 crore, and the company has reduced bank loans from Rs. 50 crore. - No references to plans for raising debt or equity capital have been made. - Discussions largely focus on operational aspects, product launches, and market expansion without indicating upcoming fundraising activities.

- For FY'27, Dhanuka Agritech is commissioning an MPP-2 plant with an expected CAPEX of Rs. 60-70 crores. - The MPP-2 plant will produce three products, including Bifenthrin, Difenoconazole, and a new product Iprovalicarb, targeting 80% capacity utilization next year. - Discussions are ongoing with multinational players, including one Japanese and one European company, for potential exclusive contract manufacturing or strategic partnerships at the Dahej manufacturing facility.

- Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years. - Growth drivers include expansion in existing products, new molecules, exports, and entry into new crops. - Favorable macroeconomic factors boost agriculture and agri-input industries. - Increasing multiple crop cycles per year due to better irrigation and marketability of produce. - Agrochemical consumption in India is low (~600 grams/hectare) compared to world averages, indicating significant growth potential. - The company focuses on specialized, value-added crops (grapes, tomato, chilli) as well as conventional crops (rice, soybean, cotton, tea). - Growth depends on better reach to every cultivating field and intensifying market penetration. - Q4 shows promise of growth, but full year may be flattish for short term. - Expansion in technical sales expected (10-20% growth next year). - New product launches scheduled for FY'27 targeting high-value crops.

- Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years, driven by favorable macroeconomic factors and increased value-added crop cultivation. - Growth will stem from existing products, new molecules, exports, and entry into new crops, supported by expanded multiple crop cycles and improved irrigation. - The company anticipates continued expansion due to low current agrochemical consumption and a large arable land base in India. - EBITDA margins guided around 18% for 9 months, with slight expected contraction of 100-110 bps annually. - Sustainable gross margin is expected around 38%, down from recent highs (~40%) due to normalization after net economic benefits. - Bayer product contributions will align with overall gross margins (~40%), with Q4 expected to show growth but full year expected to be flattish. - New product launches and improved product mix support growth trajectory.

The transcript of Dhanuka Agritech Limited's conference call on February 5, 2026, does not specifically mention current or expected order book or pending orders. However, relevant points regarding business outlook and sales visibility include: - FY'27 planning has been initiated, with expectations of a normal year ahead. - Q4 has started well with good demand in South and East Indian paddy and wheat crops. - The team is working on export sales for Bayer molecules, with better assessment expected by end of March. - Capacity utilization for the Dahej MPP-2 plant is targeted at ~80% in FY'27 for three products. - Discussions ongoing with Japanese and European companies for potential contract manufacturing at Dahej. - New product launches planned next year include two fungicides and one specialty spray enhancer. No explicit data on order backlog or pending orders is disclosed in the available transcript.